中国苏州，2021年8月19日 - 苏州艾博生物科技有限公司（以下简称“艾博生物”）今日宣布完成总额超过7亿美元的C轮融资。本轮融资由淡马锡（Temasek）、景顺发展市场基金（Invesco Developing Markets Fund）、正心谷资本、高瓴创投、云锋基金、礼来亚洲基金（LAV）、博裕投资共同领投，优山资本、高榕资本、晨壹投资、Octagon Capital、Kaiser、五源资本、和玉资本、雅惠投资、盈科资本、泰欣资本、AIHC瓴健、瑞华资本、Oriental Spring、君联资本跟投，现有股东启明创投、弘晖资本、人保资本股权、博远资本、CTS Capital等继续加持。艾博生物自2019年初成立以来，公司已经完成四轮融资，上一轮6亿元人民币的B轮融资于今年4月刚刚完成。
艾博生物成立于2019年初，是一家专注于信使核糖核酸（mRNA）药物研发的临床期创新型生物医药公司，拥有业界领先的具有自主知识产权的mRNA和纳米递送技术平台。公司已建立了丰富的产品管线，涵盖传染病防治和肿瘤免疫等领域。2020年6月，公司联合军事科学院军事医学研究院、沃森生物共同研制的新型冠状病毒mRNA疫苗（ARCoV），正式通过国家药品监督管理局临床试验批准，成为国内首个获批开展临床试验的mRNA疫苗。目前该疫苗已完成I期、II期临床研究，并已启动临床III期实验。淡马锡是一家全球投资公司，截至2021年3月31日的投资组合净值为3,810亿新元(相当于18,600亿人民币)。总部设在新加坡的淡马锡在全球9个国家拥有13个办事处。淡马锡宪章定义了其作为投资者、机构和资产管护者的三大角色，塑造了追求卓越、践行使命、造福世代的理念与使命。淡马锡提供资本促进发展，致力于赋能解决方案，以应对重大全球挑战。可持续发展是淡马锡一切行动的核心理念。淡马锡积极探寻可持续的解决方案，克服当下和未来的各种挑战，把握投资机遇，助力为广大社群构建更可持续的未来。关于景顺市场发展基金（Invesco Developing Markets Fund）景顺市场发展基金是一家在美国注册的投资公司，截至 2021 年 6 月 30 日，管理着约 532 亿美元的资产。Invesco Advisers, Inc. 担任该基金的投资顾问，是 Invesco Ltd.的间接全资子公司。
关于博裕投资 博裕投资成立于2011年，是一家专注于中国的另类资产管理公司，在香港、北京、上海和新加坡设有办公室。博裕投资拥有一支经验丰富的专业化投资队伍和企业管理团队，并通过与行业领先企业和企业家的长期合作伙伴关系，为企业提供成长性资本和战略性支持。博裕的投资组合包括一些中国市场上规模最大、管理最优、最具创新力的领头企业，覆盖了科技/媒体/商业服务、消费品和零售、金融服务和医疗健康这四个重点行业。Abogen Biosciences closes over $700mm Series C financing to accelerate its mRNA platform across multiple vaccines and diverse therapeutic areas
Suzhou, China, Aug 19, 2021 - Suzhou Abogen Biosciences Co., Ltd. (“Abogen”) announces today that it has raised more than $700 million in a series C funding, led by Temasek, Invesco Developing Markets Fund, Loyal Valley Capital (LVC), GL Ventures, Yunfeng Capital, Lilly Asia Ventures (LAV), and Boyu Capital. New investors participating in this round also include Youshan Capital, Gaorong Capital, Firstred Capital, Octagon Capital, Kaiser, 5Y Capital, MSA Capital, Alwin Capital, YINGKE PE, Tiger Jade Capital, AIHC Capital, Winfast Holding, Oriental Spring and Legend Capital. Existing investors including Qiming Venture Partners, HighLight Capital (HLC), PICC Capital Equity Investment Company Limited (PICC PE), BioTrack Capital and CTS Capital continued to participate in this round. Since its establishment in early 2019, Abogen has completed four rounds of private financing, including the series B financing of RMB 600 million completed in April this year.
This funding round will reinforce Abogen’s leading position in the field of messenger ribonucleic acid (mRNA) therapy in China, help to drive the company’s continued execution of its mRNA vaccine candidate against COVID-19 and to advance more vaccine and oncology programs into the clinic. Meanwhile, Abogen will continue to develop its mRNA platform technology and to improve on large-scale production capability, accelerating the transformation of mRNA technology into more therapeutic modalities.
Michael Yi, Partner and Co-CIO of Hillhouse said, “We have been invested in Abogen since its Series A round, and are excited to continue our support in Abogen, as a pioneer among Chinese companies to bring its mRNA vaccine candidate against COVID-19 to phase III clinical trials. It is part of GL Ventures’ mission to support innovative companies like Abogen to continuously develop and advance the clinical research of mRNA-based COVID-19 vaccines and to contribute to the fight against the COVID-19 pandemic.”
Dr. Albert Huang, Executive Director at Yunfeng Capital noted, “mRNA technology as a new approach to medicine has great long-term prospects in global markets. Once the COVID-19 pandemic struck, Abogen rapidly designed and implement the first domestic mRNA COVID-19 vaccine clinical trial, with great potential to bring breakthrough to the mRNA market in China. We believe that with Abogen's strong executive force, it is well positioned to build a leading mRNA technology platform, improving technology innovation in the biomedical industry and contributing to building a stronger public health system.”
Roy Xie, Partner of Loyal Valley Capital also commented that “Abogen is a platform company of mRNA technology. Since the outbreak of the epidemic, Abogen's team has rapidly promoted the research and development of mRNA COVID-19 vaccine with rapid directional judgment and in-depth accumulation of mRNA technology. We expect that Abogen's products can provide vaccine with solid protection, high safety and extensive accessibility for epidemic prevention in China and even the world. In addition, we also look forward to the further application of mRNA in other disease fields. In the future, Loyal Valley will support Abogen to become a global leading company in the mRNA field continuously.”
Dr. Fei Chen, Managing Partner of Lilly Asia Ventures noted, “Abogen is a leading company in mRNA vaccines in China market and has a top-class R&D and manufacturing platform for nucleic acid drugs. We are pleased to be a part of Abogen, and have a full conviction that Abogen will complete the mRNA vaccine's Phase III MRCT against COVID-19 and bring the product to global market on time. We look forward to Abogen's future progresses in the development of its multiple new pipeline products as well. LAV is committed to support Abogen sustainably going forward, and we believe Abogen will become a world-class nucleic acid drug company in the future.”
“We are grateful to the strong support from all of our investors, and I would also like to thank my team and collaborators for their incredible work and vigorous efforts in fighting COVID-19.” Said Dr. Bo Ying, Founder and CEO of Abogen. “We are leaders in mRNA therapy, harnessing the potential of this powerful and complex technology to create medicines that fulfill the unmet medical needs and aim to enhance the health and extend the lives of patients with rare and common diseases. With this new round of financing, we look forward to helping the world fight with the rapidly changing global pandemic by accelerating our COVID-19 vaccine product development, to improving its adaptiveness, and to recruiting the best industry talents to support our growth at all levels.”
Suzhou Abogen Biosciences is a clinical-stage biotechnology company advancing mRNA-based therapeutics for the treatment of cancer and infectious diseases. Since establishment in early 2019, Abogen has developed its own mRNA technology platform and proprietary delivery system which empowers the development of a series of drug product candidates including vaccines for infectious diseases and therapies for cancer. In June 2020, Abogen’s mRNA-based COVID-19 vaccine (ARCoV) has become the first mRNA vaccine approved for clinical trials in China. To date, ARCoV has completed the phase I and phase II clinical studies and is under evaluation of phase III clinical trials.
Temasek is a global investment company with a net portfolio value of S$381bn (RMB1.86t) as at 31 March 2021. Headquartered in Singapore, we have 13 offices in 9 countries around the world. Our Temasek Charter defines our three roles as an Investor, Institution and Steward, and shapes our ethos to do well, do right, and do good. As a provider of catalytic capital, we seek to enable solutions to key global challenges. Sustainability is at the core of all that we do. We actively seek sustainable solutions to address present and future challenges, as we capture investible opportunities to bring about a sustainable future for all.
About Invesco Developing Markets Fund
Invesco Developing Markets Fund is a US registered investment company which as of June 30, 2021, has approximately US$53.2 billion assets under management. Invesco Advisers, Inc. serves as the Fund’s investment adviser. Invesco Advisers, Inc. is an indirect wholly owned subsidiary of Invesco Ltd.
About Loyal Valley Capital (LVC)Loyal Valley Capital (LVC) was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM. LVC is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in companies positioned to benefit from the secular industry transformations in China. With over US$3.2 billion of assets under management, LVC mainly focuses on the following segments: New Consumer, Healthcare, and Advanced Manufacturing. We employ a thorough top-down fundamental research method to gain a deep understanding of the industries we invest in, and the inflection points they are going through. We seek to uncover insights to identify the companies benefiting the most from those fundamental changes, and help them solidify their leadership positions.
We manage capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises.
About GL Ventures
GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the venture capital arm of Hillhouse Group, and we have been investing with innovators across the world since 2005.
About Yunfeng Capital
Founded in 2010, Yunfeng Capital is a leading private equity firm in China founded by successful entrepreneurs and industry leaders. Yunfeng Capital has formed deep sector expertise and industry insights in its focused sectors, including internet plus new forms of consumption, technology and enterprise services, healthcare, accompanied and participated in the growth of a number of new economic enterprises.
About Lilly Asia Ventures (LAV)
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
About Boyu Capital
Founded in 2011, Boyu Capital is a leading Greater China-focused alternative asset management firm with offices in Hong Kong, Beijing, Shanghai and Singapore. Comprised of a team of experienced investors and business operators, Boyu Capital provides growth capital and strategic support through long-term partnerships with leading entrepreneurs and enterprises, and its portfolio includes some of the largest, best-managed and most innovative companies across the media/technology, consumer/retail, financial services, and healthcare industries in the Greater China region.